Combination therapy for colorectal cancer with abdominal spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two extra drugs (pirfenidone and sintilimab) added to standard chemotherapy before surgery. The goal is to see if this combination can help shrink or control colorectal cancer that has spread to the lining of the abdomen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your colorectal cancer must have spread to the lining of your abdomen (peritoneal metastasis), confirmed by imaging or biopsy.
- You should be planning to start your first chemotherapy for this cancer.
- You must be physically active (ECOG 0-1), meaning you can do most daily activities with little or no help.
- Your blood counts, kidney function, and liver function must be within acceptable limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines, pin and sintilimab, for people with advanced colorectal cancer that has spread to the liver and has already been treated with at least two standard therapies. The study aims to see if injecting the medicine directly into the liver tumor, combined with immunotherapy through a vein, can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.